ProtoKinetix Announces the Resumption of Phase Ib Clinical Trials for the use of AAGP® Treated Islet Cells in the Treatment of Type 1 Diabetes

0
8
ProtoKinetix announced Phase I clinical trials of AAGP® treated islet cells have resumed at the University of Alberta, Edmonton.
[ProtoKinetix, Inc. (Business Wire)]
Press Release